Skip to main content

indacaterol / glycopyrronium / mometasone (Enerzair Breezhaler®)

 

Following a full submission

AWMSG advice

Status: Recommended

Indacaterol acetate/glycopyrronium bromide/mometasone furoate (Enerzair® Breezhaler®) is recommended as an option for use within NHS Wales for the maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

 Final Recommendation: indacaterol (Enerzair Breezhaler) 3141 (PDF, 428Kb)
 Appraisal Report: indacaterol (Enerzair Breezhaler) 3141 (PDF, 212Kb)

Medicine details

Medicine name indacaterol / glycopyrronium / mometasone (Enerzair Breezhaler®)
Formulation 114 micrograms/ 46 micrograms/ 136 micrograms inhalation powder, hard capsules
Reference number 3141
Indication

Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Respiratory system
Submission type Full
Status Recommended
Advice number 0721
NMG meeting date 14/04/2021
AWMSG meeting date 19/05/2021
Date of issue 24/05/2021
Commercial arrangement